Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy

PURPOSE: Anti-programmed cell death protein 1 (PD1)±anti-cytotoxic T-lymphocyte associated protein 4 (CTLA4) immune checkpoint inhibitors (ICIs) are standard therapeutic options for metastatic melanoma. We assessed whether biologic subtype according to primary tumor type or genomic subtype can funct...

Descripción completa

Detalles Bibliográficos
Autores principales: Rose, April A N, Armstrong, Susan M, Hogg, David, Butler, Marcus O, Saibil, Samuel D, Arteaga, Diana P, Pimentel Muniz, Thiago, Kelly, Deirdre, Ghazarian, Danny, King, Ian, Kamil, Zaid Saeed, Ross, Kendra, Spreafico, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Immunotherapy Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7831745/
https://www.ncbi.nlm.nih.gov/pubmed/33483342
http://dx.doi.org/10.1136/jitc-2020-001642

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7831745/
https://www.ncbi.nlm.nih.gov/pubmed/33483342
http://dx.doi.org/10.1136/jitc-2020-001642

Ejemplares similares